An adenoviral platform for selective self-assembly and targeted delivery of nanoparticles.

Small
Vaibhav SainiMaaike Everts

Abstract

Metallic nanoparticles (NPs) can be used for the diagnosis, imaging, and therapy of tumors and cardiovascular disease. However, targeted delivery of NPs to specific cells remains a major limitation for clinical realization of these potential treatment options. Herein, a novel strategy for the specific coupling of NPs to a targeted adenoviral (Ad) platform to deliver NPs to specific cells is defined. Genetic manipulation of the gene-therapy vector is combined with a specific chemical coupling strategy. In particular, a high-affinity interaction between a sequence of six-histidine amino acid residues genetically incorporated into Ad capsid proteins and nickel(II) nitrilotriacetic acid on the surface of gold NPs is employed. The selective self-assembly of gold NPs and Ad vectors into multifunctional platforms does not negatively affect the targeting of Ad to specific cells. This opens the possibility of using Ad vectors for targeted NP delivery, thereby providing a new type of combinatorial approach for the treatment of diseases that involves both nanotechnology and gene therapy.

References

Oct 21, 1999·Journal of Structural Biology·J F HainfeldR D Powell
May 4, 2002·Science·Seung-Wuk LeeAngela M Belcher
Apr 17, 2003·Journal of the American Chemical Society·Alexander G TkachenkoDaniel L Feldheim
Jun 5, 2003·Proceedings of the National Academy of Sciences of the United States of America·Chuanbin MaoAngela M Belcher
Nov 5, 2003·Proceedings of the National Academy of Sciences of the United States of America·L R HirschJ L West
Jul 20, 2004·Nature Biotechnology·Xiaohu GaoShuming Nie
Sep 24, 2004·Current Gene Therapy·Maaike Everts, David T Curiel
Feb 26, 2005·Journal of Virology·Hongju WuDavid T Curiel
Jul 28, 2005·Lasers in Surgery and Medicine·Andre M GobinJennifer L West
Oct 6, 2005·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Willem J M MulderKlaas Nicolay
Nov 22, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Darren NesbethDavid Darling
Apr 6, 2006·Journal of the American Chemical Society·Lina LooStefan Franzen
Apr 21, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Gregory S ArnoldJeffrey S Bartlett
May 20, 2006·Science·Nathaniel L RosiChad A Mirkin
Oct 20, 2006·Journal of Nanoscience and Nanotechnology·C AlexiouH Iro

❮ Previous
Next ❯

Citations

Oct 7, 2008·Nano Letters·Evgeny V ShashkovVladimir P Zharov
Jul 2, 2011·Nature Reviews. Drug Discovery·Jin-Wook YooSamir Mitragotri
Oct 7, 2010·Protein Engineering, Design & Selection : PEDS·Mauricio G Mateu
Jan 8, 2014·Expert Opinion on Drug Delivery·Dayananda KasalaChae-Ok Yun
Nov 26, 2015·Proceedings of the National Academy of Sciences of the United States of America·Shimyn SlomovicJames J Collins
Nov 26, 2014·Chemical Reviews·Eun-Kyung LimKwangyeol Lee
Aug 7, 2010·Current Opinion in Biotechnology·Carissa M Soto, Banahalli R Ratna
Mar 3, 2009·Trends in Biotechnology·Ravi Singh, Kostas Kostarelos
Oct 29, 2009·Cancer Science·Vaibhav Saini, Robert H Shoemaker
Mar 23, 2018·Biomaterials Science·Gella Maelys Ngandeu NeubiYang Ding
Apr 8, 2020·Science China. Life Sciences·Feng LiXian-En Zhan
Jun 17, 2010·Molecular Pharmaceutics·Nittaya TresilwisedChristian Plank

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.